Bristol-Myers Squibb Co (XSWX:BMY) Other Gross PPE: CHF1,188 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
73 GF Score
Price CHF54.34
GF Value CHF45.75
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Other Gross PPE?

Bristol-Myers Squibb Co XSWX:BMY 73 Other Gross PPE is CHF1,188 Mil as of Jun. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 73/100 and a GF Value™ of CHF45.75 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Bristol-Myers Squibb Co's Other Gross PPE for the quarter that ended in Jun. 2026 was CHF1,188 Mil.

Bristol-Myers Squibb Co's quarterly Other Gross PPE declined from Dec. 2025 (CHF1,261 Mil) to Mar. 2026 (CHF1,203 Mil) and declined from Mar. 2026 (CHF1,203 Mil) to Jun. 2026 (CHF1,188 Mil).

Bristol-Myers Squibb Co's annual Other Gross PPE declined from Dec. 2023 (CHF1,202 Mil) to Dec. 2024 (CHF1,091 Mil) but then increased from Dec. 2024 (CHF1,091 Mil) to Dec. 2025 (CHF1,261 Mil).

Bristol-Myers Squibb Co Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Other Gross PPE Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 846.40 1,136.55 1,202.07 1,091.32 1,260.70

Bristol-Myers Squibb Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,037.64 1,276.94 1,260.70 1,202.99 1,187.76
XSWX:BMY
73GF Score
Bristol-Myers Squibb Co XSWX:BMY
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of CHF1,188 Mil mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Other Gross PPE of CHF1,188 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Other Gross PPE too high?
Bristol-Myers Squibb Co's current Other Gross PPE is CHF1,188 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Other Gross PPE compare to PFE and GILD?
Bristol-Myers Squibb Co's Other Gross PPE of CHF1,188 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Drug Manufacturers company?
A good Other Gross PPE depends on the Drug Manufacturers industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Other Gross PPE is CHF1,188 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (XSWX:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF45.75, compared to a current price of CHF54.34 — trading 18.8% above its estimated fair value. The current Other Gross PPE is CHF1,188 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Other Gross PPE is CHF1,188 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF54.34 is trading 18.8% above its estimated GF Value™ of CHF45.75. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for XSWX:BMY:

  • Other Gross PPE: CHF1,188 Mil
  • GF Value™: CHF45.75 vs. price of CHF54.34 (18.8% above fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
73GF Score

Get the complete analysis for XSWX:BMY

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.34
Price
CHF45.75
GF Value